In adults with overweight or obesity who do not have diabetes, the drug semaglutide lowers levels of C-reactive protein, a marker of inflammation, more than other similar drugs tested in the same...
Mechanism
Synthesis from 1 study
Semaglutide calms down overactive immune cells, which stops them from sending out inflammatory signals. With fewer of these signals reaching the liver, the liver makes less of the inflammation marker called CRP, resulting in lower levels in the blood.
Most probable mechanism
Semaglutide binds to receptors on immune cells in the blood and fat tissue, which turns down signals that cause inflammation. This reduces the release of inflammatory chemicals that tell the liver to make a protein called CRP, leading to lower levels of CRP in the blood.
Semaglutide binds to GLP-1 receptors on circulating monocytes and tissue-resident macrophages
GLP-1 receptor activation inhibits the NF-κB signaling pathway, reducing the production and release of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha
Reduced cytokine levels decrease stimulation of hepatocytes in the liver
Hepatic synthesis and secretion of C-reactive protein are suppressed as a result of diminished inflammatory signaling
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.